Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: H04AA01

Baqsimi(Glucagon)

Diabetes Mellitus

Marketing Authorisation Holder: Amphastar France Pharmaceuticals

EMA Authorisation: 16/12/2019

INN: glucagon

Indication

Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Baqsimi — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.